Literature DB >> 25023716

Characteristics and quality of life of opioid-dependent pregnant women in Austria.

Verena E Metz1, Sandra D Comer, Johanna Wuerzl, Anna Pribasnig, Gabriele Fischer.   

Abstract

This study investigated pregnant opioid-dependent women undergoing maintenance therapy, applying a multidisciplinary, case-management approach at the Addiction Clinic of the Medical University of Vienna, Austria. It aimed at characterizing the patients' basic demographic and clinical parameters and evaluating their overall quality of life (QoL) prepartum and postpartum. Three hundred ninety women were treated between 1994 and 2009 with buprenorphine (n = 77), methadone (n = 184), or slow-release oral morphine (SROM) (n = 129) on an outpatient basis throughout their pregnancy and postpartum period. All patients were subject to standardized prepartum and postpartum medical and psychiatric assessments, including QoL assessments using a German adaptation of the Lancashire QoL Profile (Berliner Lebensqualitaetsprofil), and regular supervised urine toxicologies. No medication group differences were revealed regarding basic demographic or clinical data. Mean maintenance doses (SD) at time of delivery were as follows: 64 mg (36 mg) methadone, 10 mg (6 mg) buprenorphine, 455 mg (207 mg) SROM. However, buprenorphine-medicated women showed significantly less concomitant benzodiazepine consumption than methadone- or SROM-maintained women (p = 0.005), and significantly less concomitant opioid consumption than methadone-maintained women (p = 0.033) during the last trimester. Overall QoL was good prepartum and postpartum in all measured domains except "finances" and "prospect of staying in the same housing situation," and no differences were observed in QoL among the three medication groups (p = 0.177). QoL improved significantly after delivery in most of the domains (p < 0.001). Although opioid-dependent pregnant women face high-risk pregnancies and show variability in addiction severity, they report good QoL independent of the medication administered. These results show that individually tailored treatment interventions are effective for this patient population and suggest a QoL improvement after delivery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25023716      PMCID: PMC4239179          DOI: 10.1007/s00737-014-0443-6

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  33 in total

1.  Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates.

Authors:  Neil S Seligman; Nicole Salva; Edward J Hayes; Kevin C Dysart; Edward C Pequignot; Jason K Baxter
Journal:  Am J Obstet Gynecol       Date:  2008-10       Impact factor: 8.661

2.  Changes in quality of life for pregnant women in substance user treatment: developing a quality of life index for the addictions.

Authors:  Marilyn Daley; Donald S Shepard; Denise Bury-Maynard
Journal:  Subst Use Misuse       Date:  2005       Impact factor: 2.164

3.  Neonatal abstinence syndrome after methadone or buprenorphine exposure.

Authors:  Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer
Journal:  N Engl J Med       Date:  2010-12-09       Impact factor: 91.245

4.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.

Authors:  Hendree E Jones; Rolley E Johnson; Donald R Jasinski; Kevin E O'Grady; Christian A Chisholm; Robin E Choo; Michael Crocetti; Robert Dudas; Cheryl Harrow; Marilyn A Huestis; Lauren M Jansson; Michael Lantz; Barry M Lester; Lorraine Milio
Journal:  Drug Alcohol Depend       Date:  2005-07       Impact factor: 4.492

5.  Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009.

Authors:  Gabrielle K Welle-Strand; Svetlana Skurtveit; Hendreé E Jones; Helge Waal; Brittelise Bakstad; Lisa Bjarkø; Edle Ravndal
Journal:  Drug Alcohol Depend       Date:  2012-07-25       Impact factor: 4.492

6.  The role of abstinence and activity in the quality of life of drug users engaged in treatment.

Authors:  David Best; Michael Savic; Melinda Beckwith; Stuart Honor; Justine Karpusheff; Dan I Lubman
Journal:  J Subst Abuse Treat       Date:  2013-05-22

7.  Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment.

Authors:  S M Giacomuzzi; Y Riemer; M Ertl; G Kemmler; H Rössler; H Hinterhuber; M Kurz
Journal:  Addiction       Date:  2003-05       Impact factor: 6.526

8.  Short communication: Urinary excretion of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol in a pregnant woman following heavy, chronic cannabis use.

Authors:  Andreas A Westin; Marilyn A Huestis; Kjell Aarstad; Olav Spigset
Journal:  J Anal Toxicol       Date:  2009 Nov-Dec       Impact factor: 3.367

9.  Does meeting needs improve quality of life?

Authors:  Mike Slade; Morven Leese; Mirella Ruggeri; Elizabeth Kuipers; Michele Tansella; Graham Thornicroft
Journal:  Psychother Psychosom       Date:  2004 May-Jun       Impact factor: 17.659

10.  Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience.

Authors:  Mirjana Vucinovic; Damir Roje; Zoran Vucinovic; Vesna Capkun; Marija Bucat; Ivo Banovic
Journal:  Yonsei Med J       Date:  2008-10-31       Impact factor: 2.759

View more
  3 in total

1.  Intact responses to non-drug rewards in long-term opioid maintenance treatment.

Authors:  Marie Eikemo; Philipp P Lobmaier; Mads L Pedersen; Nikolaj Kunøe; Anna Maria Matziorinis; Siri Leknes; Monica Sarfi
Journal:  Neuropsychopharmacology       Date:  2019-03-31       Impact factor: 7.853

2.  Determinants of Quality of Life in High-Dose Benzodiazepine Misusers.

Authors:  Stefano Tamburin; Angela Federico; Marco Faccini; Rebecca Casari; Laura Morbioli; Valentina Sartore; Antonio Mirijello; Giovanni Addolorato; Fabio Lugoboni
Journal:  Int J Environ Res Public Health       Date:  2017-01-04       Impact factor: 3.390

3.  Evaluation of the vaginal flora in pregnant women receiving opioid maintenance therapy: a matched case-control study.

Authors:  Alex Farr; Herbert Kiss; Michael Hagmann; Iris Holzer; Verena Kueronya; Peter W Husslein; Ljubomir Petricevic
Journal:  BMC Pregnancy Childbirth       Date:  2016-08-05       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.